Lupin to buy 2 inhalation brands from Sunovion for $75 million

Lupin will acquire two inhalation medicines, Brovana Inhalation Solution and Xopenex Inhalation Aerosol, from Sunovion Pharmaceuticals Inc. The transaction will take place for a cash consideration of $75 million. Brovana is used in the treatment of chronic bronchitis and Xopenex is used in the prevention of bronchospasm in adults, adolescents and children aged four and above.